Biotechnology · Shelton, Connecticut, United States
$4.93
-0.30% (-$0.02)2026-07-09
Smart-Money SignalNeutral · 53/100— Insiders are net buyers over 90 days ($17K, 2 buys vs 0 sales)
Net Income-$2.4M
EPS$-0.96
Market Cap$12.5M
Price Performance
Historical data including institutional events
Company Profile
L
Lewis Bender
CEO & Executive Director
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States.
Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials.
The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
